Brief: Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data And 2024 Expectations For Multiple Data Readouts And Transition To Pivotal Phase 2B/3
24/01/2024 16:12
Jan 24 (Reuters) - Moleculin Biotech Inc MBRX.O :
* MOLECULIN ANNOUNCES 2023 YEAR-END ANNAMYCIN CLINICAL
TRIALS
PRELIMINARY DATA AND 2024 EXPECTATIONS FOR MULTIPLE DATA
READOUTS AND TRANSITION TO PIVOTAL PHASE 2B/3
* MOLECULIN BIOTECH INC - WITH RECENT FINANCING IN DEC 2023,
HAVE
EXTENDED RUNWAY INTO Q4 OF 2024
Source text for Eikon: ID:nPn8Bvw20a
Further company coverage: MBRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM